Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 50: 2392-2395, 2004; 10.1373/clinchem.2004.040071
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hruska, M. W.
Right arrow Articles by Langaee, T. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hruska, M. W.
Right arrow Articles by Langaee, T. Y.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2004;50:2392-2395.)
© 2004 American Association for Clinical Chemistry, Inc.


Technical Briefs

Pyrosequencing Method for Genotyping Cytochrome P450 CYP2C8 and CYP2C9 Enzymes

Matthew W. Hruska, Reginald F. Frye and Taimour Y. Langaeea

1 College of Pharmacy, University of Florida, Gainesville, FL

aaddress correspondence to this author at: College of Pharmacy, University of Florida, PO Box 100486, Gainesville, FL 32610

The cytochrome P450 enzymes CYP2C8 and CYP2C9 play important roles in drug metabolism (1)(2)(3). Single-nucleotide polymorphisms that have been identified in the genes encoding for these enzymes may contribute to variability in drug response through alterations in metabolism. CYP2C8 expression includes five alleles: CYP2C8*1 (wild type), CYP2C8*2, CYP2C8*3 (1), CYP2C8*4(2), and CYP2C8*5 (4). The variant alleles CYP2C8*2 and *3 have been shown to encode for an enzyme with decreased activity in vitro (1), whereas CYP2C8*4 expression appears to cause decreased CYP2C8 activity (2). The allele frequency of CYP2C8*2 is 0.18 in the African-American population, whereas CYP2C8*3 and CYP2C8*4 are expressed primarily in the Caucasian population at frequencies of 0.13 and 0.075, respectively (1)(2).

Thirteen CYP2C9 alleles have been identified to date, and the majority of studies on these have focused on the importance of CYP2C9*2 (5) and CYP2C9*3 (6). CYP2C9*4 is expressed in the Asian population at an allele frequency of 0.02, but does not appear to be expressed in Caucasians or African Americans (7). CYP2C9*5 and *6 are found primarily in African Americans at frequencies of 0.017 (8) and 0.006 (9), respectively. Blaisdell et al.(10) recently identified variants designated as CYP2C9*7 through *12, which have allele frequencies ranging from 0.006 to 0.03 in African populations. The CYP2C9*8, *11, and *12 alleles have altered in vitro metabolic activities compared with the wild-type allele, CYP2C9*1 (10). Finally, CYP2C9*13 was identified in a Chinese population with an allele frequency of 0.01 and was associated with decreased CYP2C9 activity (11).

Given the importance of these enzymes in the metabolism of multiple drugs, a reliable genotyping method that is amenable to high-throughput applications would help facilitate research in this area. Several restriction fragment length polymorphism (RFLP) methods have been developed to identify CYP2C8 and CYP2C9 alleles (1)(2)(6)(7). These methods are reliable but have several disadvantages, including the time required for enzymatic digestion, lack of feasible high-throughput applications, potential for incomplete digestion, and increased cost per sample (12). Other methods, using the LightCycler (13) and tetra-primer (14) technologies, offer advantages over RFLP but do not provide direct sequencing data.

Pyrosequencing is a less laborious process that relies on the release of pyrophosphate on incorporation of a nucleotide into a DNA sequence to provide direct sequencing data. It is ideal for the determination of allelic variants, and use of multiplex pyrosequencing enables single-tube analysis of numerous target DNA sequences (15)(16). We previously developed a pyrosequencing method for CYP2C9 genotyping, but the original method detects only the two major variants found in Caucasian and African-American populations, CYP2C9*2 and *3 (12). An improvement to our previous reported method was necessary to evaluate CYP2C9*4 and *5, which are located on the same exon as CYP2C9*3. The purpose of the present study was to develop an analytical method that detects all major CYP2C8 variants; the major CYP2C9 variant, CYP2C9*2; and in a single reaction, CYP2C9*3, *4, and *5.

For DNA extraction and isolation, blood samples were collected from 50 consecutively identified healthy volunteers who signed informed consent. The study was approved by the Institutional Review Board at the University of Florida. Ethnicity was self-reported as African American (n =4; frequency, 0.08), Asian (n = 2; frequency, 0.04), Caucasian (n = 36; frequency, 0.72), and Hispanic (n = 8; frequency, 0.16). Approximately 10 mL of blood was withdrawn from each volunteer, and DNA was extracted with a QIAamp® DNA Mini Kit (Qiagen) according to the manufacturer’s instructions. Samples were stored at –20 °C after extraction.

The primers used for the PCR reactions and pyrosequencing are shown in Table 1 . PCR reactions (25 µL) consisted of 12.5 µL of HotStarTaqTM Master Mix (Qiagen), 1.5 µL of dimethyl sulfoxide, PCR primers (10 pmol), 7 µL of H2O, and 40 ng of DNA. PCR conditions were as follows: 95 °C for 15 min; 40 cycles consisting of denaturation at 94 °C for 30 s, annealing at 56 °C (55 °C for CYP2C9; 58 °C for CYP2C8 exon 8) for 30 s, and extension at 72 °C for 45 s; and final extension at 72 °C for 7 min.


View this table:
[in this window]
[in a new window]
 
Table 1. PCR and sequencing primers and allele frequencies for CYP2C8*2, *3, and *4 and CYP2C9*2, *3, *4, and *5 in all volunteers.

Genotyping was performed according to the previously described protocol (12). Briefly, PCR products (10 µL) were immobilized on streptavidin-coated Sepharose beads. Beads were isolated and treated with 700 mL/L ethanol, denaturation buffer, and wash buffer and released into a mixture of annealing buffer containing 10 pmol of sequencing primer (Table 1Up ). This solution was heated at 80 °C for 2 min and cooled to room temperature. Pyrosequencing was performed for sequence determination and allele designation in a Biotage PSQ HS 96 System, and data were captured with PSQ HS 96 SNP software. The sequences for 10 random individuals were determined in triplicate to verify the robustness of the assay.

Shown in Fig. 1A are the predicted histograms and resulting pyrograms for CYP2C8 exon 5 in individuals presenting with the following genotypes: CYP2C8*1/*1 (i), CYP2C8*1/*2 (ii), CYP2C8*2/*2 (iii), CYP2C8*1/*4 (iv), and CYP2C8*4/*4 (v). The predicted histogram and resulting pyrogram for an individual presenting as CYP2C9*1/*3 are shown in Fig. 1B . The allelic frequencies of the sample population are listed in Table 1Up . The assay detected no allelic variants in the Asian individuals, and CYP2C9*4 and *5 were not detected in the population studied. Linkage dysequilibrium was apparent between CYP2C8*3 and CYP2C9*2; seven of the eight (87.5%) volunteers with the CYP2C8*3 allele also had the CYP2C9*2 allele. Reanalysis of 10 randomly selected samples in triplicate produced the same genetic sequence information (data not shown).



View larger version (35K):
[in this window]
[in a new window]
 
Figure 1. Exon 5 sequence: predicted histograms and pyrograms.

(A), CYP2C8 exon 5 sequence used to determine genotypes for CYP2C8*2 (805A>T, indicated by box at left) and CYP2C8*4 (792C>G, indicated by box at right). (i–v), predicted histograms and pyrograms of individuals presenting with the homozygous wild-type (CYP2C8*1/*1; A/A and C/C; i), CYP2C8*1/*2 (A/T and C/C; ii), CYP2C8*2/*2 (T/T and C/C; iii), CYP2C8*1/*4 (A/A and C/G; iv), and CYP2C8*4/*4 (A/A and G/G; v) genotypes. (B), predicted histogram and pyrogram for an individual with CYP2C9*1/*3 (A/C) genotype. The determined allelic variation for CYP2C9 exon 7 (left to right) was CYP2C9*5 (1080C>G), CYP2C9*4 (1076T>C), and CYP2C9*3 (1075A>C). The order of nucleotide dispensation is located at the bottom of each pyrogram.

The pyrosequencing method presented here is directly applicable to studies involving genetic determination of CYP2C8 and CYP2C9 polymorphisms in a large sample population; our laboratory has used this assay to genotype several hundred samples (unpublished data) from various sources, including whole blood, urine, buccal swabs, and mouthwash rinses. A key advantage of pyrosequencing is that direct sequence data for each DNA are obtained, which means that little interpretation is necessary compared with other methods, such as RFLP analysis, where incomplete digestion may complicate data analysis. Furthermore, the time and cost per sample for pyrosequencing are less than for RFLP analysis (12). A method using real-time PCR to determine CYP2C8 allelic variants was recently reported (17). The PCR method offers an advantage over RFLP in that it can be modified for high-throughput applications, but it does not provide direct sequencing of DNA and therefore still requires some data interpretation. Furthermore, this reverse transcription-PCR method does not detect the CYP2C9 genotype, which is important because a linkage between the allelic variants CYP2C8*3 and CYP2C9*2 exists (18). The data gathered in our investigation support the previous report; we observed similar frequencies of CYP2C8*3 and CYP2C9*2 linkage. Further investigations with a larger sample are necessary, however. This novel method also allows the genotyping of three separate allelic variants in one PCR reaction, but we were unable to detect CYP2C9*4 and *5 carriers because the respective Asian and African-American population sample sizes were small. A larger sample of these populations would be required to identify individuals carrying these alleles. Additionally, with the recent discovery of other CYP2C9 allelic variants (10)(11), adaptations of this method could allow detection of these variants.


Acknowledgments

This project was supported in part by NIH Research Grants R01 HL68834 and MH63458, funded by the National Institute of Mental Health and the Office of Dietary Supplements, and NIH M01 RR00082.


References

  1. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  2. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6{alpha}-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002;64:1579-1589.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  3. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-355.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  4. Soyama A, Saito Y, Hanioka N, Murayama N, Nakajima O, Katori N, et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 2001;24:1427-1430.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  5. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 1997;7:203-210.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  6. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-349.[Web of Science][Medline] [Order article via Infotrieve]
  7. Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000;10:85-89.[CrossRef][Medline] [Order article via Infotrieve]
  8. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001;60:382-387.[Abstract/Free Full Text]
  9. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001;11:803-808.[CrossRef][Medline] [Order article via Infotrieve]
  10. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004;14:527-537.[CrossRef][Medline] [Order article via Infotrieve]
  11. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004;14:465-469.[CrossRef][Medline] [Order article via Infotrieve]
  12. Aquilante CL, Lobmeyer MT, Langaee TY, Johnson JA. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy 2004;24:720-726.[CrossRef][Medline] [Order article via Infotrieve]
  13. Burian M, Grosch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol 2002;54:518-521.[CrossRef][Medline] [Order article via Infotrieve]
  14. Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001;29:E88-E88.
  15. Ronaghi M. Pyrosequencing sheds light on DNA sequencing. Genome Res 2001;11:3-11.[Abstract/Free Full Text]
  16. Pourmand N, Elahi E, Davis RW, Ronaghi M. Multiplex pyrosequencing. Nucleic Acids Res 2002;30:e31.[Abstract/Free Full Text]
  17. Weise A, Grundler S, Zaumsegel D, Klotzek M, Grondahl B, Forst T, et al. Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clin Lab 2004;50:141-148.[Medline] [Order article via Infotrieve]
  18. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002;299:25-28.[CrossRef][Medline] [Order article via Infotrieve]



The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
A. Misra, J.-Y. Hong, and S. Kim
Multiplex Genotyping of Cytochrome P450 Single-Nucleotide Polymorphisms by Use of MALDI-TOF Mass Spectrometry
Clin. Chem., May 1, 2007; 53(5): 933 - 939.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hruska, M. W.
Right arrow Articles by Langaee, T. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hruska, M. W.
Right arrow Articles by Langaee, T. Y.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS